Quest Diagnostics (DGX) Beats Q4 Earnings and Revenue Estimates

Core Viewpoint - Quest Diagnostics reported quarterly earnings of $2.42 per share, exceeding the Zacks Consensus Estimate of $2.35 per share, and showing an increase from $2.23 per share a year ago, representing an earnings surprise of +2.85% [1] Financial Performance - The company achieved revenues of $2.81 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.08%, compared to $2.62 billion in the same quarter last year [2] - Over the last four quarters, Quest Diagnostics has consistently surpassed consensus EPS estimates and revenue estimates [2] Stock Performance - Quest Diagnostics shares have increased approximately 10.2% since the beginning of the year, outperforming the S&P 500's gain of 1.7% [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating expectations of outperforming the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $2.37 on revenues of $2.75 billion, and for the current fiscal year, it is $10.45 on revenues of $11.35 billion [7] - The trend of estimate revisions for Quest Diagnostics was favorable ahead of the earnings release, which may influence future stock movements [5][6] Industry Context - The Medical - Outpatient and Home Healthcare industry, to which Quest Diagnostics belongs, is currently ranked in the bottom 39% of over 250 Zacks industries, indicating potential challenges in overall industry performance [8]